Quantification of pulmonary involvement in COVID-19 pneumonia by means of a cascade of two U-nets: training and assessment on multiple datasets using different annotation criteria - Scorecard - MDSpire

Quantification of pulmonary involvement in COVID-19 pneumonia by means of a cascade of two U-nets: training and assessment on multiple datasets using different annotation criteria

  • By

  • Francesca Lizzi

  • Abramo Agosti

  • Francesca Brero

  • Raffaella Fiamma Cabini

  • Maria Evelina Fantacci

  • Silvia Figini

  • Alessandro Lascialfari

  • Francesco Laruina

  • Piernicola Oliva

  • Stefano Piffer

  • Ian Postuma

  • Lisa Rinaldi

  • Cinzia Talamonti

  • Alessandra Retico

  • October 26, 2021

  • 0 min

Share

Clinical Scorecard: Assessment of Lung Involvement in COVID-19 Pneumonia Using a Dual U-Net Approach: Training and Evaluation Across Various Datasets with Distinct Annotation Standards

At a Glance

CategoryDetail
ConditionCOVID-19 pneumonia with lung parenchyma abnormalities
Key MechanismsDeep Learning-based segmentation of lung and COVID-19 lesions on CT scans using a dual U-Net architecture
Target PopulationPatients with COVID-19 infection undergoing chest CT imaging
Care SettingRadiology and diagnostic imaging settings with CT scan availability

Key Highlights

  • COVID-19 lung abnormalities include bilateral ground-glass opacifications, consolidations, crazy-paving patterns, reversed halo sign, and vascular enlargement.
  • The LungQuant system uses a cascade of two U-Nets: the first segments lungs, the second segments COVID-19 lesions, providing quantitative lung involvement and CT severity score (CT-SS).
  • Training on heterogeneous, publicly available datasets with different annotation standards improves generalization of the DL segmentation model.

Guideline-Based Recommendations

Diagnosis

  • Use chest CT imaging to identify COVID-19 related lung abnormalities including GGO and consolidations.
  • Apply automated DL-based segmentation tools like LungQuant to quantify lung involvement objectively.

Management

  • Utilize quantitative lung lesion volume and CT-SS from segmentation outputs to assist clinical decision-making and disease severity assessment.

Monitoring & Follow-up

  • Monitor changes in lung lesion volume and CT-SS over time using serial CT scans and DL segmentation to evaluate disease progression or resolution.

Risks

  • Variability in CT acquisition protocols and annotation standards can affect segmentation accuracy.
  • Data conversion processes (e.g., DICOM to NifTI) may reduce image resolution and impact quantitative analysis.

Patient & Prescribing Data

Patients with confirmed or suspected COVID-19 undergoing chest CT

Quantitative assessment of lung involvement via DL segmentation may guide treatment intensity and monitor response but requires validation in clinical workflows.

Clinical Best Practices

  • Train DL segmentation models on large, heterogeneous datasets to improve robustness and generalizability.
  • Use dual-stage U-Net architecture: first for lung segmentation, second for lesion segmentation within lung regions.
  • Incorporate morphology-based refinement post lung segmentation to improve mask accuracy.
  • Calculate CT severity score based on percentage of lung volume affected by lesions to standardize severity assessment.

References

Original Source(s)

Related Content